Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | USP47 | Q96K76 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SLC10A6 | Q3KNW5 | 1/20 | 0.41 |
| ▸ | PRNP | P04156 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1847303 | 0.82 | ESR2 (0.58) | NPC1MAPTRAB9AMEN1HPGD | |
| SCHEMBL25983222 | 0.82 | ESR2 (0.49) | NPC1MAPTRAB9AMEN1HPGD | |
| SCHEMBL3070066 | 0.81 | ESR2 (0.45) | NPC1MAPTRAB9AMEN1HPGD | |
| SCHEMBL1848834 | 0.80 | ALDH1A1 (0.60) | NPC1MAPTRAB9AHPGDKMT2A | |
| SCHEMBL4028591 | 0.75 | MAPT (0.39) | NPC1MAPTRAB9AMEN1HPGD | |
| SCHEMBL6623690 | 0.75 | MAPT (0.39) | NPC1MAPTRAB9AMEN1HPGD | |
| SCHEMBL4032009 | 0.73 | ESR2 (0.39) | NPC1MAPTRAB9AMEN1HPGD | |
| SCHEMBL6612918 | 0.73 | ALDH1A1 (0.39) | NPC1MAPTRAB9AMEN1HPGD | |
| SCHEMBL4648233 | 0.71 | — | — | |
| SCHEMBL10933026 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718607-B2 | Atypical coupling method for the preparation of 1,2-di(thiophen-2-yl)ethene-1,2-diol compounds via a Cu(II) catalyst | QATAR UNIVERSITY (QA) | 2023-08-08 | — | — | US | disclosed |
| US-6358750-B1 | FOR COMBINATORIAL LIBRARIES; DRUG SCREENING | ARQULE, INC. | 2002-03-19 | — | — | US | disclosed |
| EP-1125937-A2 | Spiro [Pyrrolidine-2,3'-oxindole] compounds and methods of use | ARQULE, INC. (US) | 2001-08-22 | — | — | EP | disclosed |
| EP-1015430-A4 | SPIRO PYRROLIDINE-2,3'-OXINDOLE] COMPOUNDS AND METHODS OF USE | ARQULE INC (US) | 2001-01-17 | — | — | EP | disclosed |
| US-6114540-A | COMBINATORIAL LIBRARIES | ARQULE, INC. (US) | 2000-09-05 | — | — | US | disclosed |
| EP-1015430-A1 | SPIRO PYRROLIDINE-2,3'-OXINDOLE] COMPOUNDS AND METHODS OF USE | ARQULE, INC. (US) | 2000-07-05 | — | — | EP | disclosed |
| WO-1999012904-A1 | SPIRO[PYRROLIDINE-2,3'-OXINDOLE] COMPOUNDS AND METHODS OF USE | ARQULE, INC. (US) | 1999-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718607-B2 | Atypical coupling method for the preparation of 1,2-di(thiophen-2-yl)ethene-1,2-diol compounds via a Cu(II) catalyst | AP2A2, AP2A1, DNM2 | NPC1 2756/4885MAPT 3574/4885RAB9A 2017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.